‹ Lucid Group
Ch 5 · The Story Behind the Numbers
Chapter 5 · Behind the Numbers
The numbers, in the company's own words.
Every filing has a section where management explains what just happened — and why. Here's Lucid's.
↓ scroll to read
✦ The bottom line
Anyone can read the revenue line. The story — what's driving the growth, why the losses are so big, and what's funding it — is the part Lucid writes itself. Here are the threads that matter.
↓ the brief below
✦ Five threads from Lucid's FY2025 filing
1
The Gravity SUV is the growth engine now.
Revenue growth (Q1 2026 up ~*20%* YoY) is being driven by ramping the *Lucid Gravity* SUV, which reached the road in late 2024, alongside the Air sedan. A third, lower-priced *Midsize* platform is in the pipeline to widen the market.
2
Each car still loses money.
Lucid's gross margin remains deeply negative — it costs more to build a car than Lucid sells it for. Scaling production and the new factory (AMP-2 in Casa Grande, Arizona) is the path to fixing that, but it isn't fixed yet.
3
Saudi capital is the fuel.
The losses are funded by repeated capital infusions tied to the PIF. This keeps Lucid solvent but steadily dilutes shareholders and ties the company's future to one backer's continued support.
4
The technology is a second product.
Lucid doesn't just sell cars — it licenses its EV technology to other automakers, a higher-margin revenue stream that leverages its engineering lead. Small today, but strategically notable.
5
The bet beyond cars: autonomy.
Lucid frames the Gravity platform as a base for a future robotaxi, leaning on its long range and redundant electronics. It's a moonshot on top of an already-unprofitable core — upside optionality, not near-term substance.
Source · 10-K · MD&A + Business · FY2025 · Filed Feb 24, 2026
●
Read the whole story
Five threads: the Gravity ramp drives growth, each car still loses money, Saudi capital funds it, tech licensing is a second product, and a robotaxi moonshot sits on top.
You just finished
Chapter 5 · BEHIND THE NUMBERS
The Story Behind the Numbers
you now read: reading the MD&A
Up next